nach oben

Cardiovascular Toxicology

Erschienen in:

01.01.2015

Serum Free Indoxyl Sulfate Associated with In-stent Restenosis After Coronary Artery Stentings

verfasst von: Ming-Lung Tsai, I-Chang Hsieh, Cheng-Chieh Hung, Chun-Chi Chen

Erschienen in: Cardiovascular Toxicology | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Uremic toxins, including P-cresyl sulfate (PCS) and indoxyl sulfate (IS), have been found to participate in the process of atherosclerosis and patient mortality. We aim to discover if uremic toxins are related to in-stent restenosis in patients with coronary artery disease after stent implantation. We enrolled 214 patients who received coronary angioplasty with stenting and follow-up angiography between November 1995 and June 2011 with a total of 293 lesions divided into bare metal stent (BMS) or drug-eluting stent (DES) groups. Patients’ basic information and total and free form IS and PCS were used to correlate with the late loss (LL) and loss index (LI). Significantly higher LL and LI in the BMS group compared with the DES group (1.10 vs. 0.45 mm, p < 0.001, and 0.46 vs. 0.19, p < 0.001, respectively). The unadjusted correlation revealed a positive relationship between log-normalized free IS and LL, LI in the DES group (p = 0.001). After adjustment for multiple variables, the log-normalized free IS still presented as an independent predictor for the LL and LI (p = 0.012 and p = 0.031). Free IS is an independent predictor for coronary restenosis in patients receiving DES implantations. However, among patients undergoing BMS stentings, uremic toxin is not a predictor of the intracoronary restenosis.

Sarnak, M. J., Levey, A. S., Schoolwerth, A. C., Coresh, J., Culleton, B., Hamm, L. L., et al. (2003). Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation, 108, 2154–2169.CrossRefPubMed

Brunet, P., Gondouin, B., Duval-Sabatier, A., Dou, L., Cerini, C., Dignat-George, F., et al. (2011). Does uremia cause vascular dysfunction? Kidney and blood pressure research., 34, 284–290.CrossRefPubMed

Schiffer, E., Liabeuf, S., Lacroix, C., Temmar, M., Renard, C., Monsarrat, B., et al. (2011). Markers of vascular disease in plasma from patients with chronic kidney disease identified by proteomic analysis. Journal of Hypertension, 29, 783–790.CrossRefPubMed

Barreto, F. C., Barreto, D. V., Liabeuf, S., Meert, N., Glorieux, G., Temmar, M., et al. (2009). Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clinical journal of the American Society of Nephrology : CJASN., 4, 1551–1558.CrossRefPubMedCentralPubMed

Chiu, C. A., Lu, L. F., Yu, T. H., Hung, W. C., Chung, F. M., Tsai, I. T., et al. (2010). Increased levels of total P-Cresylsulphate and indoxyl sulphate are associated with coronary artery disease in patients with diabetic nephropathy. The review of diabetic studies : RDS., 7, 275–284.CrossRefPubMedCentralPubMed

Niwa, T. (2010). Indoxyl sulfate is a nephro-vascular toxin. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation., 20, S2–S6.CrossRef

Wang, C. P., Lu, L. F., Yu, T. H., Hung, W. C., Chiu, C. A., Chung, F. M., et al. (2010). Serum levels of total p-cresylsulphate are associated with angiographic coronary atherosclerosis severity in stable angina patients with early stage of renal failure. Atherosclerosis., 211, 579–583.CrossRefPubMed

Fujii, H., Nakai, K., & Fukagawa, M. (2011). Role of oxidative stress and indoxyl sulfate in progression of cardiovascular disease in chronic kidney disease. Therapeutic Apheresis and Dialysis, 15, 125–128.CrossRefPubMed

Jourde-Chiche, N., Dou, L., Cerini, C., Dignat-George, F., & Brunet, P. (2011). Vascular incompetence in dialysis patients–protein-bound uremic toxins and endothelial dysfunction. Seminars in Dialysis, 24, 327–337.CrossRefPubMed

10.

Niwa, T. (2011). Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular disease: experimental and clinical effects of oral sorbent AST-120. Therapeutic Apheresis and Dialysis, 15, 120–124.CrossRefPubMed

11.

Wu, I. W., Hsu, K. H., Lee, C. C., Sun, C. Y., Hsu, H. J., Tsai, C. J., et al. (2011). p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrology, Dialysis, Transplantation., 26, 938–947.CrossRefPubMedCentralPubMed

12.

Sato, B., Yoshikawa, D., Ishii, H., Kikuchi, R., Arima, T., Takeshita, K., et al. (2013). Indoxyl sulfate, a uremic toxin, and carotid intima-media thickness in patients with coronary artery disease. International Journal of Cardiology, 163, 214–216.CrossRefPubMed

13.

de Loor, H., Bammens, B., Evenepoel, P., De Preter, V., & Verbeke, K. (2005). Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clinical Chemistry, 51, 1535–1538.CrossRefPubMed

14.

Niwa, T., & Ise, M. (1994). Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. The Journal of Laboratory and Clinical Medicine, 124, 96–104.PubMed

15.

Dou, L., Jourde-Chiche, N., Faure, V., Cerini, C., Berland, Y., Dignat-George, F., et al. (2007). The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. Journal of Thrombosis and Haemostasis: JTH., 5, 1302–1308.CrossRefPubMed

16.

Dou, L., Bertrand, E., Cerini, C., Faure, V., Sampol, J., Vanholder, R., et al. (2004). The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney International, 65, 442–451.CrossRefPubMed

17.

Yamamoto, H., Tsuruoka, S., Ioka, T., Ando, H., Ito, C., Akimoto, T., et al. (2006). Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells. Kidney International, 69, 1780–1785.CrossRefPubMed

18.

Schepers, E., Meert, N., Glorieux, G., Goeman, J., Van der Eycken, J., & Vanholder, R. (2007). P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrology, Dialysis, Transplantation, 22, 592–596.CrossRefPubMed

19.

Meijers, B. K., Bammens, B., De Moor, B., Verbeke, K., Vanrenterghem, Y., & Evenepoel, P. (2008). Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney International, 73, 1174–1180.CrossRefPubMed

20.

Abbott, J. D., Voss, M. R., Nakamura, M., Cohen, H. A., Selzer, F., Kip, K. E., et al. (2007). Unrestricted use of drug-eluting stents compared with bare-metal stents in routine clinical practice: findings from the National Heart, Lung, and Blood Institute Dynamic Registry. Journal of the American College of Cardiology, 50, 2029–2036.CrossRefPubMed

21.

Stettler, C., Wandel, S., Allemann, S., Kastrati, A., Morice, M. C., Schomig, A., et al. (2007). Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet, 370, 937–948.CrossRefPubMed

22.

Fischman, D. L., Leon, M. B., Baim, D. S., Schatz, R. A., Savage, M. P., Penn, I., et al. (1994). A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. The New England Journal of Medicine., 331, 496–501.CrossRefPubMed

23.

Serruys, P. W., de Jaegere, P., Kiemeneij, F., Macaya, C., Rutsch, W., Heyndrickx, G., et al. (1994). A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent study group. The New England Journal of Medicine., 331, 489–495.CrossRefPubMed

24.

Hoffmann, R., Mintz, G. S., Dussaillant, G. R., Popma, J. J., Pichard, A. D., Satler, L. F., et al. (1996). Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation, 94, 1247–1254.CrossRefPubMed

25.

Kearney, M., Pieczek, A., Haley, L., Losordo, D. W., Andres, V., Schainfeld, R., et al. (1997). Histopathology of in-stent restenosis in patients with peripheral artery disease. Circulation, 95, 1998–2002.CrossRefPubMed

26.

Kornowski, R., Hong, M. K., Tio, F. O., Bramwell, O., Wu, H., & Leon, M. B. (1998). In-stent restenosis: Contributions of inflammatory responses and arterial injury to neointimal hyperplasia. Journal of the American College of Cardiology, 31, 224–230.CrossRefPubMed

27.

Komatsu, R., Ueda, M., Naruko, T., Kojima, A., & Becker, A. E. (1998). Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation, 98, 224–233.CrossRefPubMed

28.

Hill RA, Boland A, Dickson R, Dundar Y, Haycox A, McLeod C, et al. Drug-eluting stents: a systematic review and economic evaluation. Health Technol Assess. 2007;11:iii, xi-221.

29.

Lemos, P. A., Hoye, A., Goedhart, D., Arampatzis, C. A., Saia, F., van der Giessen, W. J., et al. (2004). Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the rapamycin-eluting stent evaluated at Rotterdam cardiology hospital (RESEARCH) study. Circulation, 109, 1366–1370.CrossRefPubMed

30.

Dangas, G. D., Claessen, B. E., Caixeta, A., Sanidas, E. A., Mintz, G. S., & Mehran, R. (2010). In-stent restenosis in the drug-eluting stent era. Journal of the American College of Cardiology, 56, 1897–1907.CrossRefPubMed

31.

Ota, T., Umeda, H., Yokota, S., Miyata, S., Takamura, A., Sugino, S., et al. (2009). Relationship between severity of renal impairment and 2-year outcomes after sirolimus-eluting stent implantation. American Heart Journal, 158, 92–98.CrossRefPubMed

32.

Wu, I. W., Hsu, K. H., Hsu, H. J., Lee, C. C., Sun, C. Y., Tsai, C. J., et al. (2012). Serum free p-cresyl sulfate levels predict cardiovascular and all-cause mortality in elderly hemodialysis patients–a prospective cohort study. Nephrology, Dialysis, Transplantation, 27, 1169–1175.CrossRefPubMed

33.

Meijers, B. K., Van Kerckhoven, S., Verbeke, K., Dehaen, W., Vanrenterghem, Y., Hoylaerts, M. F., et al. (2009). The uremic retention solute p-cresyl sulfate and markers of endothelial damage. American Journal of Kidney Diseases, 54, 891–901.CrossRefPubMed

34.

Lin, C. J., Chuang, C. K., Jayakumar, T., Liu, H. L., Pan, C. F., Wang, T. J., et al. (2013). Serum p-cresyl sulfate predicts cardiovascular disease and mortality in elderly hemodialysis patients. Archives of Medical Science: AMS., 9, 662–668.CrossRefPubMedCentralPubMed

35.

Adijiang, A., Goto, S., Uramoto, S., Nishijima, F., & Niwa, T. (2008). Indoxyl sulphate promotes aortic calcification with expression of osteoblast-specific proteins in hypertensive rats. Nephrology, Dialysis, Transplantation, 23, 1892–1901.CrossRefPubMed

36.

Niwa, T. (2010). Uremic toxicity of indoxyl sulfate. Nagoya Journal of Medical Science, 72, 1–11.PubMed

Titel: Serum Free Indoxyl Sulfate Associated with In-stent Restenosis After Coronary Artery Stentings
verfasst von: Ming-Lung Tsai
I-Chang Hsieh
Cheng-Chieh Hung
Chun-Chi Chen
Publikationsdatum: 01.01.2015
Verlag: Springer US
Erschienen in: Cardiovascular Toxicology / Ausgabe 1/2015
Print ISSN: 1530-7905
Elektronische ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-014-9270-2

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2015

Cardiogenic shock due to acute tramadol intoxication

Torsades de Pointes Induced by the Concomitant Use of Ivabradine and Azithromycin: An Unexpected Dangerous Interaction

β1-Adrenoceptor Autoantibodies Affect Action Potential Duration and Delayed Rectifier Potassium Currents in Guinea Pigs

Cardiovascular Effects of Phaleria macrocarpa Extracts Combined with Mainstay FAC Regimen for Breast Cancer

H2O2 Induces Myocardial Hypertrophy in H9c2 Cells: A Potential Role of Ube3a

Modified High-Density Lipoproteins by Artificial Sweetener, Aspartame, and Saccharin, Showed Loss of Anti-atherosclerotic Activity and Toxicity in Zebrafish